Probuphine®
Maintenance treatment of Opioid Use Disorder (OUD)
ApprovedActive (Acquired, planning re-launch)
Key Facts
Indication
Maintenance treatment of Opioid Use Disorder (OUD)
Phase
Approved
Status
Active (Acquired, planning re-launch)
Company
About ReacX Pharmaceuticals
ReacX Pharmaceuticals is a private, pre-revenue biotech leveraging its acquired ProNeura® drug delivery platform to develop long-acting implantable therapeutics for chronic conditions. Its lead asset is Probuphine®, an approved but currently withdrawn implant for opioid use disorder (OUD), which the company plans to relaunch. The pipeline also includes a nalmefene implant for OUD relapse prevention and potential programs for chronic pruritus, targeting significant unmet needs in addiction medicine and beyond with its sustained-release technology.
View full company profile